Drug-induced gingival hyperplasia therapeutic agent

Compounds promoting NR4A1 expression, such as 6-gingerol, address the challenge of drug-induced gingival hyperplasia by reducing collagen production and inflammation, providing a non-invasive therapeutic solution.

JP2024162156APending Publication Date: 2024-11-21HIROSHIMA UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023077438
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-09
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current treatments for drug-induced gingival hyperplasia, a side effect of antiepileptic drugs, calcium channel blockers, or immunosuppressants, involve drug modification or invasive procedures like gingivectomy, posing risks and complications, and there is a lack of effective non-invasive therapeutic options.

Method used

Development of a therapeutic agent containing compounds like 6-gingerol, 8-gingerol, 10-gingerol, paradol, 1-dehydro-6-gingerdione, and tetrahydrocurcumin, which promote NR4A1 expression to treat drug-induced gingival hyperplasia by suppressing collagen production and reducing inflammation.

Benefits of technology

The compounds effectively treat drug-induced gingival hyperplasia by promoting NR4A1 expression, reducing collagen production, and providing anti-inflammatory effects, offering a non-invasive and effective therapeutic option.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024162156000007
    Figure 2024162156000007
  • Figure 2024162156000008
    Figure 2024162156000008
  • Figure 2024162156000009
    Figure 2024162156000009
Patent Text Reader

Abstract

To provide a medicine that exerts excellent therapeutic effect to drug-induced gingival hyperplasia.SOLUTION: An NR4A1 expression promoter has a gingerol derivative, tetrahydrocurcumin, and a compound such as paradol or a salt thereof as active ingredients.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a therapeutic agent for medicinal gingival hyperplasia. [Background technology]

[0002] Drug-induced gingival hyperplasia is a periodontal disease characterized by gingival hyperplasia, a side effect of antiepileptic drugs, calcium antagonists, or immunosuppressants. At present, there is no fundamental treatment, and the only options are to change the medication taken or to remove the thickened gingiva. In cases where there are multiple alternative drugs such as antihypertensive drugs, it may be possible to change the medication, but in cases such as antiepileptic drugs and immunosuppressants, changing the medication carries the risk of recurrence of the original disease or rejection of organ transplants, and it is not easy to change the medication. In patients with vascular disorders such as severe acute heart disease and cerebral infarction, strict blood pressure control is required, and even if the medication is an antihypertensive, it is not easy to change the medication. Therefore, there is a need for a treatment method that does not require a change in medication or gingivectomy. In recent years, the efficacy of lovastatin in treating hyperplasia has been reported (Non-Patent Document 1), but this has not yet been put to clinical use.

[0003] Recently, the present inventors have found that NR4A1 (nuclear receptor subfamily 4 group A member 1), a nuclear receptor with no identified biological ligand, is associated with drug-induced gingival hyperplasia. In other words, they have demonstrated that drugs suppress the expression of NR4A1 in the gingiva, resulting in failure to suppress collagen production and thickening of the gingiva, and that administration of cytosporone B (CsnB), a compound that increases the expression of NR4A1, improves drug-induced gingival hyperplasia (Non-Patent Document 2).

[0004] Furthermore, the inventors have reported that butylidenephthalide (BP), contained in Angelica sinensis (Touki), a plant of the Umbelliferae family, increases the expression of NR4A1 mRNA and protein in gingival fibroblasts and reduces the expression of collagen induced by TGF-β, and further that, when administered to a mouse model of drug-induced gingival hyperplasia, it can treat the hyperplasia (Non-Patent Document 3).

[0005] On the other hand, gingerols such as 6-gingerol are pungent components contained in ginger, and their pharmacological effects have been reported so far, including anti-inflammatory effects (Non-Patent Document 4), anti-cancer effects (Non-Patent Document 5), and pharmacological effects against neurodegenerative diseases (Non-Patent Document 6). However, their effect against drug-induced gingival hyperplasia has not been known so far. [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] Assaggaf MA et al., Am J Pathol. 185(6):1588-99. 2015 [Non-Patent Document 2] Hatano S., Matsuda S. et al., FASEBJ. 35(7):e21693. 2021 [Non-Patent Document 3] 65th Spring Annual Meeting of the Japanese Society of Periodontology, June 2-3, 2022, Keio Plaza Hotel, Oral Presentation 2: "Effectiveness of Butylidenephthalide in Treating Drug-Induced Gingival Hyperplasia" [Non-Patent Document 4] Yucel C et al., Front Pharmacol. 5;13:902551. 2022 [Non-Patent Document 5] Nafees S et al., Anticancer Agents Med Chem. 21(4):428-432. 2021 [Non-Patent Document 6] Arcusa R et al., Front Nutr. 18;9:809621. 2022 Summary of the Invention [Problem to be solved by the invention]

[0007] An object of the present invention is to provide a drug that exhibits excellent therapeutic effects against drug-induced gingival hyperplasia. [Means for solving the problem]

[0008] As a result of intensive research to solve the above-mentioned problems, the inventors have found that a compound represented by the following formula (1) or (1') or a salt thereof promotes the expression of NR4A1 and is useful for the treatment of drug-induced gingival hyperplasia.

[0009] That is, the present invention relates to the following 1) and 2). 1) An NR4A1 expression promoter comprising a compound represented by the following formula (1) or (1') or a salt thereof as an active ingredient: 2) A therapeutic agent for medicinal gingival hyperplasia, comprising as an active ingredient a compound represented by the following formula (1) or a salt thereof:

[0010] [ka] [In the formula, X represents the following X1 to X5: The group selected from TIFF2024162156000002.tif51165 is shown. Effect of the Invention

[0011] The compound of the present invention has an effect of promoting the expression of NR4A1 and exerts a therapeutic effect against drug-induced gingival hyperplasia. Therefore, according to the present invention, drug-induced gingival hyperplasia can be effectively treated. [Brief description of the drawings]

[0012] [Figure 1] NR4A1 expression promoting effect of the compound of the present invention. [Diagram 2] Inhibitory effect of 6-gingerol on type 1 collagen expression. [Diagram 3] Inhibitory effect of 6-gingerol on IL-6 expression. [Figure 4] Therapeutic effect of 6-gingerol on drug-induced gingival hyperplasia. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] In the compound represented by formula (1) of the present invention, The compound where X is X1 is known as 6-gingerol (also known as (S)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-3-decanone). The compound where X is X2 is known as 8-gingerol (also known as (S)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-3-dodecanone). The compound where X is X3 is known as 10-gingerol (also known as (S)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-3-tetradecanone). The compound where X is X4 is known as tetrahydrocurcumin (also known as 1,7-bis(4-hydroxy-3-methoxyphenyl)heptane-3,5-dione). The compound where X is X5 is known as Paradol (also known as 1-(4-hydroxy-3-methoxyphenyl)-decan-3-one). The compound represented by formula (1') is also known as 1-Dehydro-6-gingerdione (also known as (E)-1-(4-hydroxy-3-methoxyphenyl)dec-1-ene-3,5-dione). In this specification, the compounds represented by formulas (1) and (1') are also referred to as "compounds of the present invention."

[0014] When the compound of the present invention has optical isomers, it may be any optical isomer or a mixture of optical isomers. In addition, when the compound of the present invention has stereoisomers (cis type, trans type), all stereoisomers are included in the present invention. The compounds of the present invention also include hydrates, various solvates and crystal polymorphs.

[0015] Examples of the "salt" of the compound of the present invention include salts with alkali metals such as sodium and potassium; salts with alkaline earth metals such as calcium and magnesium; ammonium salts; salts with nitrogen-containing organic bases such as trimethylamine and triethylamine; and base addition salts with basic amino acids such as arginine, lysine, and ornithine.

[0016] 6-gingerol, 8-gingerol, 10-gingerol, paradol, and 1-dehydro-6-gingedione are all pungent components found in ginger (Zingiber officinale) of the ginger family, and tetrahydrocurcumin is a component found in turmeric (Curcuma longa) of the ginger family. The compound of the present invention can be produced by chemical synthesis, but can also be prepared by extracting it from natural products such as ginger or turmeric and purifying it using a silica gel column, etc. Alternatively, commercially available products can be used.

[0017] As shown in the Examples below, the compound of the present invention increases the expression of NR4A1 mRNA in human gingival fibroblasts (HGF). Therefore, the compound of the present invention or a salt thereof is an NR4A1 expression promoter and can be used as a medicine for promoting the expression of NR4A1. "NR4A1" (nuclear receptor subfamily 4 group A member 1) refers to a protein known as Gene ID: 3164, MIM ID: 139139. In the present invention, "promotion of NR4A1 expression" includes promotion of expression at the gene level and promotion of expression at the protein level. Promotion of expression at the gene level includes promotion of expression of mRNA and promotion of transcription to mRNA, and promotion of expression at the protein level includes promotion in translation. Each expression level can be measured based on any parameter.

[0018] As mentioned above, it has been revealed that in drug-induced gingival hyperplasia, the expression of NR4A1 in the gingiva is suppressed by the drug, resulting in uncontrollable collagen production and thickening of the gingiva, and that the symptoms are improved by increasing the expression of NR4A1 (Non-Patent Document 2). Therefore, the compound of the present invention having an NR4A1 expression promoting effect or a salt thereof is useful as a medicine that exhibits excellent therapeutic effects against drug-induced gingival hyperplasia. In fact, it has been confirmed that 6-gingerol suppresses the expression of type 1 collagen, improves the symptoms in a drug-induced gingival hyperplasia model animal, and also has an anti-inflammatory effect.

[0019] In the present invention, drug-induced gingival hyperplasia refers to a periodontal disease characterized by gingival hyperplasia, which is a side effect of antihypertensive drugs (calcium antagonists), antiepileptic drugs (phenytoin), or immunosuppressants (cyclosporine). The hypertrophied gingiva becomes a breeding ground for oral bacterial infections, and aggravates caries and periodontal disease. In severe cases, it is accompanied by tooth movement, deterioration of aesthetics, and reduced chewing ability. Therefore, the "treatment" of drug-induced gingival hyperplasia of the present invention includes not only the prevention and treatment of drug-induced gingival hyperplasia, but also the inhibition of collagen production in gingival tissue, reduction of inflammation, reduction of symptoms associated with drug-induced gingival hyperplasia, and maintenance to prevent recurrence.

[0020] The NR4A1 expression promoter or the therapeutic agent for drug-induced gingival hyperplasia of the present invention is not limited in the form of administration as long as it is effective against drug-induced gingival hyperplasia, but local administration by external preparations, injections, etc. is preferred. For example, the agent is filled in a syringe or the like and injected into a periodontal pocket. It can also be administered to the gingival hyperplasia during periodontal surgical treatment. In that case, it is also preferred to absorb the therapeutic agent of the present invention into a sheet or sponge in order to act at a constant concentration for a long period of time. It is also preferred to locally administer a paste containing the therapeutic agent of the present invention after oral care.

[0021] Dosage forms for topical administration include external preparations such as creams, ointments, and lotions, which are produced using pharma- ceutically acceptable carriers or diluents based on normal formulation preparation methods, as well as injections whose main component is, for example, an aqueous solvent (e.g., water, an aqueous lactic acid solution, ethyl alcohol, propylene glycol, macrogol, etc.) The injections can be in the form of a powder, and can be dissolved in a solvent such as purified water immediately before use.

[0022] The amount of the compound of the present invention or a salt thereof to be incorporated in each of the above-mentioned dosage unit forms varies depending on the symptoms of the patient to which it is to be administered or on the dosage form, but it is generally desirable that the amount per dosage unit form be about 0.1 to 2000 mg for external preparations and about 0.1 to 500 mg for injections.

[0023] The dosage of the NR4A1 expression promoter or therapeutic agent for drug-induced gingival hyperplasia of the present invention varies depending on the age, sex, symptoms, etc. of the subject to be administered, but in the above-mentioned local administration, it is usually 0.1 to 2000 mg, preferably 1 to 1000 mg, and more preferably 10 to 500 mg of the compound of the present invention or a salt thereof per dosage unit.

[0024] In addition, the NR4A1 expression promoter or the therapeutic agent for drug-induced gingival hyperplasia of the present invention may be used in combination with other drugs, such as antibacterial agents and anti-inflammatory agents, as long as the combination does not impair the effectiveness of the other drugs.

[0025] The present invention will be described in more detail below with reference to examples and test examples, but the present invention is not limited to these. EXAMPLES

[0026] <Compound> ·6-gingerol (FUJIFILM Wako Pure Chemical Corporation), ·10-gingerol (FUJIFILM Wako Pure Chemical Corporation), Paradol (MedChemExpress), ·Tetrahydrocurcumin (Combi-Blocks), Rac-[6]-gingerol (Toronto Research Chem) <6-gingerol racemic mixture>, ·1-Dehydro-6-gingerdione (ChemFaces)

[0027] <Cell culture> Immortalized gingival fibroblasts (GT1, Kamata et al., J Oral Pathol Med 33:417-423. 2004) were kindly provided by Professor Ohta of the Department of Oral Health Care, Hiroshima University. Gingival fibroblasts were cultured in DMEM medium (Sigma) containing 10% (v / v) FBS at 37°C and 5 Vol% CO2.

[0028] <Gene expression analysis by quantitative PCR method> In the following examples, real-time PCR was performed using Light Cycler and SYBR green (Applied Biosystems, CA, USA) to evaluate relative mRNA expression levels. The fold change of the genes of interest was calculated using the ΔΔCt method, and the CT values ​​generated from the qPCR system were directly used to calculate the relative gene expression of the target and control samples with GAPDH as a normalizer. The primer sequences are shown below. 1) NR4A1 Forward: CCAAGTACATCTGCCTGGCTAAC (SEQ ID NO: 1) Reverse: CTGTTCGGACAACTTCCTTCACC (SEQ ID NO: 2) 2)COL1A1: Forward: GCTATGATGAGAAATCAAACGCAG (SEQ ID NO: 3) Reverse: TCATCTCCATTCTTTCCAGG (SEQ ID NO: 4) 3) IL6 Forward: GGAGACTTGCCTGGTGAAAA (SEQ ID NO: 5) Reverse: GTCAGGGGTGGTTATTGCAT (SEQ ID NO: 6) 4) GAPDH Forward: AACGTGTCAGTGGACCTG (SEQ ID NO: 7) Reverse: AGTGGGTGTCGCTGTTGAAGT (SEQ ID NO: 8)

[0029] <Statistical analysis> Mean differences in gene expression between groups were analyzed by analysis of variance, followed by multiple comparison tests (Tukey's test or Dunnett's test) if significant.

[0030] Example 1: Promoting effect of the compound of the present invention on NR4A1 expression (1) Method Gingival fibroblasts were cultured until confluent, then cultured in FBS-free DMEM for 4 hours, and then treated with each compound at a final concentration of 50 μM for 1 hour. Total RNA was extracted using RNA iso plus (registered trademark) (Takara Bio). cDNA synthesis was performed using Toyobo's reverse transcriptase, ReverTra Ace (registered trademark). Using the synthesized cDNA, NR4A1 mRNA expression was evaluated by the quantitative PCR method described above.

[0031] (2) Results Increases in NR4A1 were confirmed with 6-gingerol, 10-gingerol, paradol, 1-dehydro-6-gingeredione, and tetrahydrocurcumin (Figure 1). In particular, a high increase in NR4A1 expression was confirmed with tetrahydrocurcumin.

[0032] Example 2: Inhibitory effect of 6-gingerol on type 1 collagen expression (1) Method Gingival fibroblasts were cultured until confluent and then cultured in FBS-free DMEM for 4 hours. After stimulation with TGF-β (10 ng / ml) for 12 hours, 6-gingerol (100 μg / ml) was administered for 12 hours. cDNA was synthesized as described above, and COL1A1 mRNA expression was evaluated.

[0033] (2) Results 6-Gingerol suppressed the mRNA expression of type 1 collagen that was increased by TGF-β (Figure 2).

[0034] Example 3: Inhibitory effect of 6-gingerol on IL-6 expression (1) Method Gingival fibroblasts were cultured until confluent, and then cultured in FBS-free DMEM for 4 hours. TNF-α (10 ng / ml) was added and 6-gingerol was added for 24 hours either without stimulation or at 50 or 100 μg / ml. cDNA was synthesized as described above, and the mRNA expression of inflammatory cytokine (IL-6) was evaluated.

[0035] (2) Results 6-gingerol was found to have the effect of reducing IL-6 mRNA expression induced by inflammatory cytokines (TNF-α) (Figure 3).

[0036] Example 4: Therapeutic effect of 6-gingerol on drug-induced gingival hyperplasia (1) Method According to the description of Okanobu et al., J Immunol Methods Jun;445:31-36., wild type mice c57 / BL6 (male, 8 weeks old) were ligated with silk thread on the maxillary second molar, periodontitis was induced for one week, and cyclosporine (50mg / kg / day) dissolved in castor oil was administered intraperitoneally for four weeks to develop gingival hyperplasia. After the onset of gingival hyperplasia, 6-gingerol (10mg / kg / day) was mixed with methylcellulose and applied to the oral cavity with a cotton ball every day for two weeks, and the evaluation of gingival hyperplasia in the oral cavity was visually evaluated.

[0037] (2) Results In a mouse hyperplasia model, local administration of 6-gingerol was shown to have a therapeutic effect on drug-induced gingival hyperplasia (Figure 4).

Claims

1. The following formula (1) or (1′): 【Chemistry 1】 [In the formula, X represents the following X1 to X5: 【change】 represents a group selected from the following. An NR4A1 expression promoter comprising as an active ingredient a compound represented by the formula:

2. The following formula (1) or (1′): 【Chemistry 2】 [In the formula, X represents the following X1 to X5: 【change】 represents a group selected from the following. A therapeutic agent for medicinal gingival hyperplasia, comprising as an active ingredient a compound represented by the formula: